Repligen Corporation, a life sciences company focused on bioprocessing technology, appointed Olivier Loeillot to the newly created position of president and chief commercial officer (CCO).

Loeillot served a combined 12 years with Cytiva and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as bioprocess president from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies, and enterprise solutions. Prior to Cytiva, he worked at Lonza for 12 years advancing to vice president sales, Lonza Custom Manufacturing. Loeillot joins Repligen from his most recent role as CEO of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets.

At Repligen, Loeillot will oversee all business units as well as the commercial organization, driving the commercial and corporate key account strategy and expanding the market impact of Repligen’s business units in bioprocessing, while collaborating with the company’s executive team in advancing the overall bioprocess growth plan.

Tony Hunt, CEO at Repligen, said, “We are delighted to welcome Olivier to our team at Repligen. His proven management and leadership experience in global bioprocessing markets strengthens our executive team and will enable us to reach the next level of growth for the company, as we expand our market footprint and execute on commercial and business strategies.”

 Loeillot said, “I am excited to join Repligen, which has quickly become the innovation leader in bioprocessing. I look forward to applying my commercial and global business experience to the company, working closely with Tony and the rest of the executive team, to continue Repligen’s successful growth and to advance Repligen to the next stage of its development.”